JP2014500278A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014500278A5 JP2014500278A5 JP2013543410A JP2013543410A JP2014500278A5 JP 2014500278 A5 JP2014500278 A5 JP 2014500278A5 JP 2013543410 A JP2013543410 A JP 2013543410A JP 2013543410 A JP2013543410 A JP 2013543410A JP 2014500278 A5 JP2014500278 A5 JP 2014500278A5
- Authority
- JP
- Japan
- Prior art keywords
- dose
- composition
- days
- initial dose
- interval
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42199210P | 2010-12-10 | 2010-12-10 | |
| US61/421,992 | 2010-12-10 | ||
| PCT/US2011/064496 WO2012079093A2 (en) | 2010-12-10 | 2011-12-12 | Dosage and administration of bispecific scfv conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014500278A JP2014500278A (ja) | 2014-01-09 |
| JP2014500278A5 true JP2014500278A5 (OSRAM) | 2015-01-29 |
Family
ID=46207797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013543410A Withdrawn JP2014500278A (ja) | 2010-12-10 | 2011-12-12 | 二重特異性ｓｃＦｖコンジュゲートの投薬量および投与 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20140017264A1 (OSRAM) |
| EP (1) | EP2648753A4 (OSRAM) |
| JP (1) | JP2014500278A (OSRAM) |
| AU (1) | AU2011341337A1 (OSRAM) |
| CA (1) | CA2819554A1 (OSRAM) |
| WO (1) | WO2012079093A2 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20131113T1 (hr) | 2007-02-16 | 2014-01-17 | Merrimack Pharmaceuticals, Inc. | Protutijela protiv erbb3 i njihova uporaba |
| NZ602084A (en) | 2010-03-11 | 2014-07-25 | Merrimack Pharmaceuticals Inc | Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers |
| ES2949159T3 (es) | 2010-05-06 | 2023-09-26 | Novartis Ag | Composiciones y métodos de uso para anticuerpos terapéuticos de proteína 6 relacionada con lipoproteínas de baja densidad (LRP6) |
| BR112012028326A2 (pt) | 2010-05-06 | 2017-03-21 | Novartis Ag | anticorpo multivalente isolado, anticorpos biparatópicos isolados, ácido nucleico, vetor, composição farmacêutica, método de obtenção dos referidos anticorpos, bem como uso do dos mesmos |
| EP2678359A4 (en) * | 2011-02-24 | 2015-01-28 | Merrimack Pharmaceuticals Inc | COMBINATION THERAPIES WITH ANTI-ERBB3 MEDIUM |
| JP2015502741A (ja) | 2011-11-04 | 2015-01-29 | ノバルティス アーゲー | 低比重リポタンパク質関連タンパク質６（ｌｒｐ６）−半減期延長構築物 |
| EP2847226A4 (en) * | 2012-05-11 | 2016-05-11 | Merrimack Pharmaceuticals Inc | DOSAGE AND ADMINISTRATION OF BIS SPECIFIC SCFV CONJUGATES IN COMBINATION WITH ANTICROBIAL AGENTS |
| US20150202287A1 (en) * | 2012-08-30 | 2015-07-23 | Merrimack Pharmaceuticals, Inc. | Combination therapies comprising anti-erbb3 agents |
| WO2015100459A2 (en) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| US20160045596A1 (en) | 2014-08-05 | 2016-02-18 | Merrimack Pharmaceuticals, Inc. | Combination therapies for treating her2-positive cancers that are resistant to her2-targeted therapies |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| CN106729743B (zh) | 2015-11-23 | 2021-09-21 | 四川科伦博泰生物医药股份有限公司 | 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090226429A1 (en) * | 2001-05-25 | 2009-09-10 | Human Genome Sciences, Inc. | Antibodies That Immunospecifically Bind to TRAIL Receptors |
| CN102057054B (zh) * | 2008-04-11 | 2015-06-10 | 梅里麦克制药股份有限公司 | 人血清白蛋白接头以及其结合物 |
-
2011
- 2011-12-12 EP EP11847515.1A patent/EP2648753A4/en not_active Withdrawn
- 2011-12-12 US US13/992,460 patent/US20140017264A1/en not_active Abandoned
- 2011-12-12 AU AU2011341337A patent/AU2011341337A1/en not_active Abandoned
- 2011-12-12 JP JP2013543410A patent/JP2014500278A/ja not_active Withdrawn
- 2011-12-12 CA CA2819554A patent/CA2819554A1/en not_active Abandoned
- 2011-12-12 WO PCT/US2011/064496 patent/WO2012079093A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014500278A5 (OSRAM) | ||
| RU2014152115A (ru) | Комбинированная терапия с использованием антител к клаудину 18.2 для лечения рака | |
| TW201023855A (en) | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan | |
| JP2017523187A5 (OSRAM) | ||
| RU2014152107A (ru) | Комбинированная терапия с использованием антител к клаудину 18.2 для лечения рака | |
| JP2019517549A5 (OSRAM) | ||
| JP2019196370A5 (OSRAM) | ||
| JP2009518441A5 (OSRAM) | ||
| JP2013538796A5 (OSRAM) | ||
| JP2014533279A5 (OSRAM) | ||
| JP2011511071A5 (OSRAM) | ||
| JP2010529026A5 (OSRAM) | ||
| US20140017264A1 (en) | Dosage and administration of bispecific scfv conjugates | |
| SI2625199T1 (en) | Procedures for treating psoriasis using IL-17 antagonists | |
| JP2016528247A5 (OSRAM) | ||
| JP2014114288A5 (OSRAM) | ||
| RU2015127794A (ru) | Введение антисмысловых олигонуклеотидов, комплементарных человеческому аполипопротеину в | |
| JP2015500822A5 (OSRAM) | ||
| FI3356386T3 (fi) | Melanokortiini-4-reseptoripolkuun liittyvien häiriöiden hoitamismenetelmä | |
| EP3174985A1 (en) | An antagonistic pd-1 aptamer and its applications in cancer therapy related applications | |
| JP2010500370A5 (OSRAM) | ||
| JP2015517511A5 (OSRAM) | ||
| TW201536319A (zh) | 抗腫瘤劑及抗腫瘤效果增強劑 | |
| TW201206474A (en) | Treating breast cancer with anti-IL-19 antibody | |
| TW201043225A (en) | Antitumour combination comprising AVE8062 and sorafenib |